ENXTBR:ARGX
ENXTBR:ARGXBiotechs

How Positive ADAPT SERON Results at argenx (ENXTBR:ARGX) Have Changed Its Investment Story

argenx SE recently announced positive topline results from the pivotal ADAPT SERON study, showing that VYVGART® achieved statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living for AChR-Ab seronegative gMG patients compared to placebo. This marks a potential milestone as the company prepares to seek FDA approval for expanded labeling, which could allow VYVGART to be used across all adult seronegative gMG patient subtypes for the first...
ENXTBR:PAY
ENXTBR:PAYElectronic

European Dividend Stocks To Enhance Your Portfolio

As European markets face challenges from political instability and renewed tariff uncertainties, the pan-European STOXX Europe 600 Index has seen a decline, reflecting broader concerns about economic resilience. In such an environment, dividend stocks can offer stability and income potential to investors looking to enhance their portfolios by providing regular payouts that may help cushion against market volatility.